Conduit Pharmaceuticals Files 8-K on Corporate Changes
Ticker: CDTTW · Form: 8-K · Filed: Nov 19, 2024 · CIK: 1896212
| Field | Detail |
|---|---|
| Company | Conduit Pharmaceuticals Inc. (CDTTW) |
| Form Type | 8-K |
| Filed Date | Nov 19, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $11.50 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, management-change, filing
TL;DR
Conduit Pharma 8-K: Board shakeup, officer changes, and amended bylaws filed Nov 19.
AI Summary
Conduit Pharmaceuticals Inc. filed an 8-K on November 19, 2024, reporting on events as of November 14, 2024. The filing covers the departure of directors, election of new directors, appointment of officers, and compensatory arrangements. It also includes amendments to articles of incorporation or bylaws and changes in the fiscal year, along with financial statements and exhibits.
Why It Matters
This 8-K filing signals significant internal corporate governance and structural changes at Conduit Pharmaceuticals, which could impact its strategic direction and operational management.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with amendments to governing documents, can indicate internal shifts that may affect future performance or strategy.
Key Players & Entities
- Conduit Pharmaceuticals Inc. (company) — Registrant
- Murphy Canyon Acquisition Corp. (company) — Former company name
- November 14, 2024 (date) — Earliest event reported date
- November 19, 2024 (date) — Filing date
FAQ
What specific changes were made to Conduit Pharmaceuticals' board of directors?
The filing indicates the departure of directors and the election of new directors, but the specific names and number of directors are not detailed in this summary section.
Were there any changes in the executive officer positions at Conduit Pharmaceuticals?
Yes, the filing explicitly mentions the appointment of certain officers.
What is the significance of the 'Compensatory Arrangements of Certain Officers' mentioned in the filing?
This suggests that the company is disclosing details about the compensation packages for its key executives, which could be of interest to investors.
Did Conduit Pharmaceuticals amend its articles of incorporation or bylaws?
Yes, the filing states that amendments to articles of incorporation or bylaws were part of the reported items.
When did Conduit Pharmaceuticals change its name from Murphy Canyon Acquisition Corp.?
The date of the name change from Murphy Canyon Acquisition Corp. to Conduit Pharmaceuticals Inc. was November 30, 2021.
Filing Stats: 1,246 words · 5 min read · ~4 pages · Grade level 10.6 · Accepted 2024-11-19 17:00:36
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share CDT The Nasdaq
- $11.50 — of Common Stock at an exercise price of $11.50 CDTTW The Nasdaq Stock Market LLC
Filing Documents
- form8-k.htm (8-K) — 52KB
- ex3-1.htm (EX-3.1) — 6KB
- ex10-1.htm (EX-10.1) — 195KB
- 0001493152-24-046849.txt ( ) — 507KB
- cdt-20241114.xsd (EX-101.SCH) — 4KB
- cdt-20241114_def.xml (EX-101.DEF) — 29KB
- cdt-20241114_lab.xml (EX-101.LAB) — 36KB
- cdt-20241114_pre.xml (EX-101.PRE) — 27KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 19, 2024 CONDUIT PHARMACEUTICALS INC. By: /s/ David Tapolczay Name: Dr. David Tapolczay Title: Chief Executive Officer